TY - JOUR
T1 - Structure-based design, synthesis and evaluation of a novel family of PEX5-PEX14 interaction inhibitors against Trypanosoma
AU - Napolitano, Valeria
AU - Mróz, Piotr
AU - Marciniak, Monika
AU - Kalel, Vishal C.
AU - Softley, Charlotte A.
AU - Janna Olmos, Julian D.
AU - Tippler, Bettina G.
AU - Schorpp, Kenji
AU - Rioton, Sarah
AU - Fröhlich, Tony
AU - Plettenburg, Oliver
AU - Hadian, Kamyar
AU - Erdmann, Ralf
AU - Sattler, Michael
AU - Popowicz, Grzegorz M.
AU - Dawidowski, Maciej
AU - Dubin, Grzegorz
N1 - Publisher Copyright:
© 2022 The Authors
PY - 2022/12/5
Y1 - 2022/12/5
N2 - Trypanosomiases are neglected tropical diseases caused by Trypanosoma (sub)species. Available treatments are limited and have considerable adverse effects and questionable efficacy in the chronic stage of the disease, urgently calling for the identification of new targets and drug candidates. Recently, we have shown that impairment of glycosomal protein import by the inhibition of the PEX5-PEX14 protein-protein interaction (PPI) is lethal to Trypanosoma. Here, we report the development of a novel dibenzo[b,f][1,4]oxazepin-11(10H)-one scaffold for small molecule inhibitors of PEX5-PEX14 PPI. The initial hit was identified by a high throughput screening (HTS) of a library of compounds. A bioisosteric replacement approach allowed to replace the metabolically unstable sulphur atom from the initial dibenzo[b,f][1,4]thiazepin-11(10H)-one HTS hit with oxygen. A crystal structure of the hit compound bound to PEX14 surface facilitated the rational design of the compound series accessible by a straightforward chemistry for the initial structure-activity relationship (SAR) analysis. This guided the design of compounds with trypanocidal activity in cell-based assays providing a promising starting point for the development of new drug candidates to tackle trypanosomiases.
AB - Trypanosomiases are neglected tropical diseases caused by Trypanosoma (sub)species. Available treatments are limited and have considerable adverse effects and questionable efficacy in the chronic stage of the disease, urgently calling for the identification of new targets and drug candidates. Recently, we have shown that impairment of glycosomal protein import by the inhibition of the PEX5-PEX14 protein-protein interaction (PPI) is lethal to Trypanosoma. Here, we report the development of a novel dibenzo[b,f][1,4]oxazepin-11(10H)-one scaffold for small molecule inhibitors of PEX5-PEX14 PPI. The initial hit was identified by a high throughput screening (HTS) of a library of compounds. A bioisosteric replacement approach allowed to replace the metabolically unstable sulphur atom from the initial dibenzo[b,f][1,4]thiazepin-11(10H)-one HTS hit with oxygen. A crystal structure of the hit compound bound to PEX14 surface facilitated the rational design of the compound series accessible by a straightforward chemistry for the initial structure-activity relationship (SAR) analysis. This guided the design of compounds with trypanocidal activity in cell-based assays providing a promising starting point for the development of new drug candidates to tackle trypanosomiases.
KW - Chagas disease
KW - Glycosomal protein import
KW - HTS
KW - Human African trypanosomiasis
KW - PPI inhibition
KW - Structure-based drug design
UR - http://www.scopus.com/inward/record.url?scp=85139010625&partnerID=8YFLogxK
U2 - 10.1016/j.ejmech.2022.114778
DO - 10.1016/j.ejmech.2022.114778
M3 - Article
C2 - 36194937
AN - SCOPUS:85139010625
SN - 0223-5234
VL - 243
JO - European Journal of Medicinal Chemistry
JF - European Journal of Medicinal Chemistry
M1 - 114778
ER -